fda compounded semaglutide enforcement news Drug compounders sue over declaration ending Wegovy shortage Compound versions of GLP-1 drugs
Description
The change in body weight was 8.82% after 24 weeks of liraglutide treatment, whereas it was stable in the placebo group
2019 in a randomized, double blind placebo controlled trial found the percentage of patients with adverse events related to diabetic retinopathy during the trial was 7.1% (113 of 1591 patients) with oral semaglutide and 6.3% (101 of 1592) with a placebo [56]
Stewart WK, Fleming LW
PlexusDx supports informed decision-making by helping patients and providers evaluate whether GLP-1 treatment aligns with individual clinical profiles, including genetic predispositions in peptide metabolism pathways
